Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 7
Submit an article Journal homepage
273
Views
30
CrossRef citations to date
0
Altmetric
Drug Evaluations

Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis

C Bracewell Newcastle University, Musculoskeletal Research Group and Wilson Horne Immunotherapy Centre, Institute of Cellular Medicine, Newcastle-upon-Tyne, UK
, SpR MBBS MRCP,
JD Isaacs Professor of Clinical Rheumatology, Newcastle University, Arthritis Research Campaign, Musculoskeletal Research Group and Wilson Horne Immunotherapy Centre, Institute of Cellular Medicine, Newcastle-upon-Tyne, UK
, PhD FRCP,
P Emery Professor of Rheumatology, Chapel Allerton Hospital, Leeds General Infirmary, Leeds, UK
, MA MD FRCP &
WF Ng arc Clinical Senior Lecturer in Rheumatology, Faculty of Medical Sciences, University of Newcastle, Arthritis Research Campaign, Institute of Cellular Medicine, Musculoskeletal Research Group, Framlington Place, Newcastle-upon-Tyne, NE2 4HH, UK +44 191 2228125; +44 191 2225455; [email protected]
, PhD MRCP
Pages 909-919 | Published online: 12 Jun 2009

Bibliography

  • Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2006;65(Suppl 3):2-15
  • Fan PT, Leong KH. The use of biological agents in the treatment of rheumatoid arthritis. Ann Acad Med Singapore 2007;36:128-34
  • Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10
  • Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904
  • Dörner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003;15:246-52
  • Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford 2005;44(Suppl 2):3-7
  • Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006;20:915-28
  • Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29 (Suppl 2):105-12
  • Tanaka Y. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Intern Med 2007;46:1313-5
  • Roche Products Limited. Mabthera 100 mg and 500 mg concentrate for solution for infusion. Available from: http://emc.medicines.org.uk/medicine/2570/SPC/Mabthera + 100mg + and + 500mg + concentrate + for + solution + for + infusion/ [Last accessed on 22 May 2009]
  • Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11
  • Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
  • Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32
  • De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33
  • Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
  • Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20
  • Leandro MJ, Cooper N, Cambridge G, et al. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 2007;46:29-36
  • Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21
  • Dörner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008;20:263-8
  • Roque R, Ponce R, Burleson F, et al. Influenza virus host response of C57Bl/6 mice treated with TACI-Ig. Immunopharmacol Immunotoxicol 2006;28:13-32
  • Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-21
  • Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18:305-17
  • Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302
  • Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-17
  • Zhang X, Park CS, Yoon SO, et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 2005;17:779-88
  • Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008;180:3655-9
  • Carbonatto M, Yu P, Bertolino M, et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 2008;105:200-10
  • Kalled SL. BAFF: a novel therapeutic target for autoimmunity. Curr Opin Investig Drugs 2002;3:1005-10
  • Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9
  • Stohl W, Metyas S, Tan SM, et al. Inverse assoication between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63(9):1096-103
  • Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115(11):3083-92
  • Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 2008;8:1805-14
  • Seshasayee D, Valdez P, Yan M, et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-88
  • Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710
  • Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007;63:647-56
  • Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58:61-72
  • Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008;48:406-17
  • Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-3
  • Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167. Published online 8 November 2006, doi:10.1186/ar2076
  • Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50
  • Ansell SM, Witzig TE, Inwards DJ, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008;14:1105-10
  • Rossi J-F, Moreaux J, Rose M, et al. A Phase I/II study of atacicept, an inhibitor of APRIL and BLyS, in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) [Abstract PO-601]. Haematologica 2007;92(Suppl 2):153
  • La DT, Collins CE, Yang HT, et al. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor α antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis 2008;67:1132-8
  • Genovese MC, Kaine JL, Kohen MD, et al. Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20 + B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (Ph I/II ACTION study) [Abstract #6]. Arthritis Rheum 2006;54(Suppl 9):S66
  • Østergaard M, Wiell C, Sierakowski S, et al. HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis [Abstract #2122]. Arthritis Rheum 2006;54(9 Suppl):S230
  • Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-7
  • Mckay J, Chwalinska-Sadowska H, Boling E, et al. Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard care of therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population [Abstract 1920]. Arthritis Rheum 2005;52(Suppl 9):S710-1
  • Ponce R. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol Pathol 2009;37:89-99
  • Darce JR, Arendt BA, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-86
  • Sims GP, Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood 2005;105:4390-8
  • Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006;65(Suppl 3):34-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.